Figure 10Sponsor’s Submitted Cost Comparison16

Generic Name (Brand Name)Strength, Dosage FormPricea ($)Recommended Dosage RegimenAnnualc Drug Cost ($)Difference in Annualc Cost
Vedolizumab SC (ENTYVIO®)108 mg, pre-filled syringe or pen$822.5000108 mg, Q2W$21,458.44-
Comparators
Vedolizumab IV (ENTYVIO®)300 mg, vial$3,290.0000300 mg, Q8W$21,458.44$0.00
Adalimumab (HUMIRA®)40 mg, vial$769.970040 mg, Q2W$20,087.97$1,370.47
Inflixumab (INFLECTRA®)100 mg, vial$525.00005 mg/kg, Q8W$12,683.31$8,775.13
Infliximab (REMICADE®)100 mg, vial$987.56005 mg/kg, Q8W$23,858.14($2,399.70)
Infliximab (RENFLEXIS™)100 mg, vial$493.00005 mg/kg, Q8W$11,910.23$9,548.21
Ustekinumab (STELARA®)90 mg, vial$4,593.140090 mg, Q8W$29,957.93($8,499.49)

IV, intravenous; Q2W, every two weeks; Q8W, every eight weeks; SC, subcutaneous.

a

Price of vedolizumab SC provided by Takeda Canada Inc. Prices for comparators referenced from Ontario, as a proxy.5,6 Excludes mark-up and dispensing fees.

b

Recommended dosage regimens referenced from each product’s respective product monograph.7–12

c

Annual cost provided assuming maintenance treatment of CD. For treatments with weight-based dosing (infliximab), the average patient weight for patients receiving vedolizumab SC in the VISIBLE 2 trial was used.1

Healthcare ResourceFrequency per yearUnit CostaTreatment(s)
Administration costs associated with intravenously infused products.Based on recommended dosing regimens, infused comparators are to be administered 6.5 times per year. Administration costs are applied once per product administration.$288.36Vedolizumab IV (ENTYVIO®), infliximab (INFLECTRA®, REMICADE®, RENFLEXIS™)
a

Costs referenced from Ontario, as a proxy.14–15

From: Sponsor’s Summary of the Cost Information

Cover of Clinical and Economic Review Report: Vedolizumab (ENTYVIO SC)
Clinical and Economic Review Report: Vedolizumab (ENTYVIO SC): Takeda Canada Inc. Indication: Crohn disease [Internet]
Copyright © 2021 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.